[Pharmacogenomics].
Copyright policy )[Pharmacogenomics].
A number of genetic polymorphisms have been reported to affect responsiveness to (pharmacokinetics and pharmacodynamics of) pharmaceuticals, and this study field, pharmacogenomics, is rapidly developing. Several genetic biomarkers associated with drug safety and efficacy have been already applied to diagnostic and prescribing purposes. In this review, we would like to outline the recent progress in pharmacogenomics, focusing on anti-cancer drugs tegafur (with reference to CYP2A6 polymorphisms), irinotecan (UGT1A1), and cetuximab (somatic mutations in KRAS), and an anti-platelet drug clopidogrel (CYP2C19). This review also addresses genetic markers for drug-induced severe cutaneous adverse reactions (HLA-B) and myopathy(SLCO1B1).
Ticlopidine, Pharmacogenetics, Antibodies, Monoclonal, Cetuximab, Humans, Camptothecin, Antibodies, Monoclonal, Humanized, Irinotecan, Clopidogrel, Tegafur
Ticlopidine, Pharmacogenetics, Antibodies, Monoclonal, Cetuximab, Humans, Camptothecin, Antibodies, Monoclonal, Humanized, Irinotecan, Clopidogrel, Tegafur
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!